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Abstract: This work combines expertise in stem cell biology and bioengineering to define the 
system for geometric control of proliferation and differentiation of myogenic progenitor cells. 
We have created an artificial niche of myogenic progenitor cells, namely, modified extracellular 
matrix (ECM) substrates with spatially embedded growth or differentiation factors (GF, DF) 
that predictably direct muscle cell fate in a geometric pattern. Embedded GF and DF signal 
progenitor cells from specifically defined areas on the ECM successfully competed against 
culture media for myogenic cell fate determination at a clearly defined boundary. Differentiation 
of myoblasts into myotubes is induced in growth-promoting medium, myotube formation 
is delayed in differentiation-promoting medium, and myogenic cells, at different stages of 
proliferation and differentiation, can be induced to coexist adjacently in identical culture media. 
This method can be used to identify molecular interactions between cells in different stages of 
myogenic differentiation, which are likely to be important determinants of tissue repair. The 
designed ECM niches can be further developed into a vehicle for transplantation of myogenic 
progenitor cells maintaining their regenerative potential. Additionally, this work may also serve 
as a general model to engineer synthetic cellular niches to harness the regenerative potential 
of organ stem cells. 
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Introduction
Skeletal muscle is maintained and repaired by endogenous stem cells, called satellite 
cells, which constitute all the regenerative potential in this organ (Zammit et al 2002; 
Sherwood et al 2004). Satellite cells reside in direct contact with the differentiated, 
multinucleated muscle cells (myofibers or myotubes), under the basal lamina. Two 
to five percent of all muscle nuclei are in satellite cells in the adult muscle (Morgan 
and Partridge 2003). In resting adult muscle, 99.9% of satellite cells are mitotically 
quiescent until muscle injury activates satellite cells to proliferate and differentiate 
along myogenic lineage into the myogenic progenitor cells, which progress to become 
fusion-competent myoblasts (Morgan and Partridge 2003). Myoblasts are still capable 
of division but can also fuse to form new multinucleated myofibers. This coordinated 
cell-fate determination, which consists of cell expansion followed by differentiation, 
serves to repair or replace the damaged muscle (Morgan and Partridge 2003). 
Muscle regeneration is a complex process of tissue remodeling that involves 
myogenesis, formation of new neuro-muscular junctions, and re-vascularization and 
is regulated by an intricate network of biochemical pathways, including those initiated 
by inflammatory cytokines, growth factors, integrins, and the evolutionarily conserved 
Notch, Wnt, and Shh signaling pathways (Husmann et al 1996; Yang et al 1996; 
Taverna et al 1998; Conboy and Rando 2002; Pola et al 2003; Seale et al 2003; Tidball 
2005). Injury promotes the release of growth factors that bind to extracellular matrix 
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(ECM) proteins, such as proteoheparan sulfates (Husmann 
et al 1996). During later stages of regeneration, interactions 
between the remodeled ECM and cell-surface integrin 
receptors play a key role in the adhesion and spreading of 
newly generated myoblasts, and thus the organization of 
the regenerated muscle fibers (Disatnik and Rando 1999; 
Disatnik et al 2002; Zaidel-Bar et al 2004). Among the best-
characterized growth factors, the most important in muscle 
repair are FGF-2, IGF-1, TGF-β, and GDF-8 (myostatin). 
FGF-2 promotes the proliferation of myogenic progenitor 
cells and delays their differentiation, in part by inhibiting the 
expression of myogenic regulatory factors (Maley et al 1994; 
Miller et al 2000). IGF-1 promotes myogenic differentiation 
(Florini et al 1996) and is a key determinant of muscle mass, 
as it enhances protein synthesis in differentiated myofibers 
(Bodine et al 2001; Latres et al 2005). At the same time, 
IGF-1 down-regulates protein degradation in muscle cells 
(Sandri et al 2004; Stitt et al. 2004) and has anti-apoptotic 
effects (Lawlor and Rotwein 2000; Downward 2004). Also, 
IGF-1 reduces age-related muscle atrophy and attenuates 
experimentally induced muscle wasting (Chakravarthy et 
al 2001; Shavlakadze et al 2005). TGF-β and the muscle-
specific TGF-β family member, myostatin, are on the 
opposite end of the proliferative spectrum. These factors 
inhibit proliferation of myogenic progenitor cells during 
both embryonic development and adult muscle regeneration 
(McPherron et al 1997; Thomas et al 2000; Moustakas et al 
2002; Zimmers et al 2002; McCroskery et al 2003). Myostatin 
mRNA has been shown in vivo to accumulate progressively 
during muscle repair (Armand et al 2003), while the mRNA 
levels of its inhibitor, follistatin, has been shown to be present 
in the mono-nucleated muscle cells located near the injury 
site and in newly formed myofibers (Armand et al 2003). 
This well-studied interplay of growth factors in regenerating 
muscle serves to restore cellular homeostasis during injury 
repair (Husmann et al 1996).
In stark contrast to young animals, aged organisms 
produce very few myoblasts in response to muscle injury, and 
thus not enough cells are available to form new myofibers 
(Schultz and Lipton 1982; Bockhold et al 1998; Conboy 
et al 2003). Decline in the generation of myoblasts in aged 
muscle has been proven not to be caused by a physical loss of 
satellite cells related to aging (Conboy et al 2003), but rather 
by a failure in their ability to become activated and proliferate 
in response to injury. Remarkably, the intrinsic satellite cell 
regenerative potential is not irreversibly lost with age, but 
rather is simply not triggered in old muscle due to extrinsic 
systemic factors (Conboy et al 2005). 
It is of great interest to the scientific community to be 
able to control regeneration in chronically degenerating or 
aged organs either by in situ activation of endogenous stem 
cells or by stem cell transplantation. Satellite cells have often 
been viewed as a promising source of regenerative reserves 
in transplantation studies. These cells are numerous in adults, 
readily available, and relatively easily harvested; they rapidly 
expand in culture and their progeny myogenic progenitor 
cells also proliferate and are able to differentiate into new 
muscle tissue in vivo and in vitro (Morgan and Partridge 
2003). However, despite the decades of attempts using 
electroporation and other techniques, there is no known cell 
transplantation-based cure for repair of aged or pathologically 
degenerating muscle (Partridge 2004). Notably, taking into 
account the dependence of the satellite cells’ regenerative 
potential on the extrinsic environment described above, the 
ability of transplanted cells to repair muscle efficiently is likely 
to be inhibited in the aged environment of a degenerating 
organ, even if the transplantation itself were successful. 
Therefore, several key requirements appear to be 
necessary for improving both the success of transplantation 
and the regenerative outcome. We hypothesized that creating 
an optimized micro-environment for myogenic progenitor 
cells would provide these requirements by allowing 
deliberate control of their expansion and differentiation, 
thereby overcoming the negative effects of the endogenous 
physiologic niche. 
This study focuses on creating biologically active artificial 
niches for myogenic progenitor cells – ECM substrates 
containing spatially embedded growth factors (GF) and 
differentiation factors (DF) – which predictably direct muscle 
cell fate in a defined geometric pattern. The very first steps 
for a successful design of such an artificial stem cell niche 
are to test specific combinations of GF and DF that are able 
to direct myogenic cell fate in vitro, as well as to create a 
reliable method of spatial response of myogenic progenitor 
cells adherent to ECM modified with GF and DF. These goals 
have been accomplished in the present work.
The results presented here firstly demonstrate that it 
is possible to create modified ECM adhesion substrates 
with embedded GF or DF in a geometrically defined area. 
Secondly, such modified ECM substrates override external 
conditions imposed by culture media and promote specific 
cell fate determination of myogenic progenitor cells. Finally, 
our data directly show that cells with different cell fates 
determined by their exposure to the geometrically embedded 
GF or DF can coexist adjacent to each other on the same plate 
sharing identical culture media.International Journal of Nanomedicine 2006:1(2) 205
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Methods
Animal strain and primary myoblast 
cultures
C57BL/6 mice were obtained from Jackson Laboratories and 
housed at UC Berkeley Animal Care Facility. Both muscle 
injury and acquisition of muscle progenitor cells from myofiber 
fragments were performed as previously published (Conboy 
and Rando 2002). Briefly, 3 days after muscle injury, hind leg 
muscle was dissected and dissociated into myofibers, which 
were cultured overnight, during which time activated satellite 
cells gave rise to colonies of myogenic progenitor cells. 
These cells, called primary myoblasts, were then expanded 
and used in this work. Myofibers as well as myoblasts were 
cultured on ECM-coated plates (1:500 ECM-phosphate 
buffer solution [PBS]) in growth-promoting medium (GM).   
Reagents
Antibodies to bromodeoxyuridine (BrdU) and to embryonic 
myosin heavy chain (eMHC), and nuclear stain Hoechst were 
obtained from Abcam Inc. (Cambridge, MA, USA), Vector 
Laboratories (Burlingame, CA, USA), and Sigma (St Louis, 
MO, USA), respectively. Secondary antibodies were obtained 
from Molecular Probes (Eugene, OR, USA). TGF-β, GDF-8, 
b-FGF, α-TGF-β, and IGF-1 were all obtained from R&D 
Labs (Minneapolis, MN, USA). Follistatin was obtained from 
Sigma (St Louis, MO, USA). Ham’s F10, DMEM medium, 
and p/s were obtained from Mediatech Inc. (Herndon, VA, 
USA) and OptiMEM medium and FBS were from Invitrogen 
Corp. (Carlsbad, CA, USA). Horse serum (HS) was also 
obtained from Mediatech Inc. (Herndon, VA, USA). PBS 
was obtained from Fisher Scientific (Fairlawn, NJ, USA) 
and ECM gel from Engelbreth Holm-Swarm (EHS) mouse 
sarcoma from Sigma (St Louis, MO, USA). This ECM gel 
contains collagens, non-collagenous glycoproteins, and 
proteoglycans. Precisely, its major component is laminin, 
and it also contains collagen type IV, heparan sulfate 
proteoglycan, entactin, and other minor components. 
Slides and cylinders
Two- and 4-chamber culture slides were obtained from BD 
Biosciences (Bedford, MA, USA) and cloning cylinders were 
obtained from VWR International (West Chester, PA, USA).
Slide preparation
Two-chamber slides were pre-coated with ECM gel 1 day 
prior to experiments. To create a separate environment, 
cloning cylinders were placed into the middle of each   
chamber during pre-coating. The pre-coated slide with 
a cylinder was allowed to congeal overnight at room 
temperature. A seal between the interior and the exterior of 
the cloning cylinder was formed during the gelation of the 
ECM as the cylinder penetrated the ECM due to gravity. This 
seal is vital in preventing exchange of GF or DF between 
the interior and the exterior environment of the cylinder. 
To facilitate uniform cell adhesion and proliferation, the 
seal must also be such that it does not damage the ECM 
underneath it when the cylinder is removed prior to cellular 
seeding. To achieve these parameters, different concentrations 
of ECM were tested and a concentration of 40 µg/ml was 
finally selected.
For control experiments, 4-chamber slides were used and 
pre-coated in similar fashion without the cylinders.
Growth and differentiation factor 
preparation and placement
GF: b-FGF (0.05 µg/ml), follistatin (0.5 µg/ml), and α-TGF-β 
(10 µg/ml); and DF: GDF-8 (0.1 µg/ml), IGF-1 (0.5 µg/ml), 
and TGF-β (0.02 µg/ml) were prepared separately in a 
ECM–PBS solution (12 µg/ml) and placed inside different 
cylinders of each chamber. In order to maintain the seal 
formed, pressure equilibrium between the outside and inside 
environments of the cylinders was maintained while adding 
factors. This allows us to confine the factors to a specific 
area on the slide determined by the geometry and size of the 
inner diameter of the cloning cylinders. Different cloning 
cylinders were also tested and those with the best surface 
finishing of the cross section (Scienceware cloning cylinders 
from VWR International) produced the best seal and thus the 
best geometric boundary.
This preparation was kept overnight (~24 hours) at 4°C 
to allow integration of factors into the ECM layer.
Media preparation and cell placement
GM consisted of Ham’s F10 + 20% FBS + FGF-2 (5 ng/
ml) + 1% p/s, differentiation-promoting medium (DM) 
consisted of DMEM + 2% HS + 1% p/s, and neutral medium 
(NM) consisted of OptiMEM + 5% FBS + 1% p/s. Prior to 
seeding cells into each chamber, all residual liquid inside 
chambers and cylinders was aspirated and afterwards 
cloning cylinders were removed from the chambers, leaving 
behind areas of modified ECM with embedded GF and DF. 
Myoblasts were re-suspended into desired media (GM, DM, 
or NM), seeded under each experimental condition into 
corresponding chambers, and cultured for 48 hours.International Journal of Nanomedicine 2006:1(2) 206
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Immunofluorescence analysis
In order to measure cell proliferation or differentiation by 
immunofluorescence as previously described (Conboy and 
Rando 2002), myoblasts were fixed with 70% EtOH in PBS 
after 36 or 48 hours of specific culture conditions. BrdU was 
added to cultured media 2 hours prior to cell fixation in order 
to label replicating cells. After fixing cells, they were washed 
with staining buffer (PBS + 1% FBS + 0.5% Na azide) and 
permeabilized in staining buffer containing 0.25% Triton X-
100. Afterwards, cells were incubated with antibodies specific 
for both proliferation (BrdU) and differentiation (eMHC) for 
1 hour at room temperature. Hoechst stain was added during 
secondary antibody incubation. For BrdU detection, cells 
were incubated with 4M HCl at room temperature prior to 
permeabilization, to denature DNA. α-eMHC was used at 
1:25 hybridoma supernatant dilution and α-BrdU at 2.5 µg/
ml. Secondary antibodies and Hoechst were used at 1:500 
hybridoma supernatant dilution.
Quantification and statistics
Cells were counted from triplicate experiments with at least 
300 cells per experiment. Cells expressing BrdU proliferation 
marker were counted as proliferating cells. Cells expressing 
eMHC and containing 2 or less nuclei per fiber were counted 
as early-differentiating cells D1 and those with more than 2 
nuclei per fiber were D2. Statistical significance confidence 
intervals were analyzed with p-value test (Anova: Single 
Factor) and error bars.
Results
The main goal of this study was to direct myogenic 
progenitor cells to either proliferation or differentiation 
when these cells coexist on the same dish but are exposed 
to different areas of their adhesion substrate. We have used 
as the adhesion substrate ECM gels with geometrically 
embedded factors that differ from each other in their 
effects on cell fate (see references in Table 1). In this way, 
cells are subjected to the same culture conditions imposed 
by the media but to different culture conditions imposed 
by the adhesion substrates. Specifically, we set out to 
promote differentiation of myogenic progenitor cells into 
myotubes in GM, growth of progenitor cells in DM, and 
more efficient proliferation or robust differentiation in NM.
To do this, ECM gels have been modified with a 
combination of GF and DF which had been previously shown 
to direct myogenic proliferation or differentiation when added 
to culture media (Husmann et al 1996; Conboy and  Rando 
2002; Pola et al 2003; Tidball 2005; Wagers and  Conboy 
2005). The factors used in this study and their main effects 
on myogenesis have been summarized in Table 1. 
Primary myogenic progenitor cell cultures have been 
generated from satellite cells activated by muscle injury, as 
Table 1  Growth- and differentiation-promoting factors (GF, DF) used (see Methods section for more detailed information about these reagents; 
references about their effects on myogenesis are given here)
Factor
Effects on 
myogenesis
GF 
combinations
DF 
combinations References
FGF-2
Enhanced proliferation 
of myogenic progenitor 
cells
            +
(Maley et al 1994; Miller et al 2000)
GDF-8 
(myostatin)
Inhibition of proliferation 
of myogenic progenitor 
cells
+
(McPherron et al 1997; Thomas et al 2000;  
Zimmers et al 2002;  
McCroskery et al 2003)
Follistatin Inhibition of myostatin + (Armand et al 2003)
IGF-1
Enhanced differentiation 
and increased myofiber 
size–mass              +
(Florini et al 1996; Lawlor and Rotwein 2000;  
Bodine et al 2001; Heszele and Price 2004;  
Sandri et al 2004; Shavlakadze et al 2005)
TGF-β
Inhibitor of cell cycle 
progression, promotes 
differentiation and 
wound healing
         + (Derynck and Zhang 2003; Jakubowiak et al. 2000; 
Massague and Chen 2000; Massague et al 2000)
α-TGF-β
Neutralization of TGF-β 
activity
+
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previously described (Conboy and  Rando 2002; Wagers and   
Conboy 2005). These myogenic cells or primary myoblasts 
have been cultured in 3 specific media conditions: GM, 
DM, and NM (see Methods section for media composition 
details). 
We embedded geometrically combinations of GF and 
DF (Table 1) into ECM gel, which is frequently used 
as a substrate for cell growth in vitro and is similar to 
physiological substrate of myogenic progenitor cells in vivo. 
We aimed to examine whether these factors would be able to 
override the cell fate imposed by the aforementioned media 
and, at the same time, whether a clearly defined boundary 
between cells with alternative myogenic cell fates could be 
created by their adhesion to modified ECM substrates which 
contain either GF or DF.
To achieve these goals, we have developed the experi-
mental technique described in detail in the Methods section 
and summarized in Scheme 1. Briefly, ECM gels were 
divided into different geometric areas using cloning cylinders 
and mixtures of either GF or DF were placed inside them, 
creating modified areas of ECM which contained factors, 
vs the unmodified ECM areas. Afterwards cells were 
uniformly seeded onto the whole ECM substrate, so that after 
approximately 1 hour cells adhered to both unmodified and 
Scheme 1
1. ECM:PBS coating (1:100) + cylinder placement. Overnight @RT
2. GF/DF placement inside cylinder. Overnight @4°C
3. Removal of cylinders
4. Media and cells placement
5. Addition of BrdU 2 hours prior to fixation
6. Cells fixing after 48 hours
7.   Indirect immunofluorescence (BrdU for proliferation, eMHC for differentiation, 
nuclear dye Hoechst)
modified ECM areas and shared the same media. Adherence 
of cells to unmodified and modified ECM was simultaneous 
and there was no difference in cell survival (data not shown). 
Experiments with GF or DF uniformly embedded into the 
whole ECM area have also been carried out as positive 
controls.
Figure 1 Geometric control of terminal myogenic differentiation in GM. Myogenic 
progenitor cells have been plated at 50% confluency in chamber slides in GM. 
(a) GM with unmodified ECM (GM) and GM with DF-modified ECM (GM + DF). 
(b) Quantification of P, differentiated cells with less than 2 nuclei (D1 = early stage 
of differentiation), and differentiated cells with more than 2 nuclei (D2 = later stage 
of differentiation). On unmodified ECM, there is a significantly higher percentage 
of proliferative cells vs differentiated cells. Looking at cells grown on DF-modified 
ECM, we see higher numbers of differentiated cells, but most cells do not form 
multinucleated myotubes. (c) The boundary between unmodified ECM substrate 
(outside) and DF-modified ECM (inside). Geometric boundary between DF-
modified and unmodified ECM substrate was created as described in Methods. 
Cells were uniformly seeded throughout the ECM area, cultured for 48 hours and 
fixed. Immunofluorescence was performed with the indicated antibodies: α-BrdU 
(red), α-eMHC (green), and Hoechst (blue) was used to label all nuclei. Proliferation 
(incorporation of BrdU) is observed in GM with unmodified ECM and inhibited 
proliferation and differentiation (expression of eMHC) is observed in GM with 
DF-modified ECM.  Similar results have been obtained in at least 3 independent 
experiments. Magnification: (a) 20x; (c) 10x.
Abbreviations for Figures 1–3, Scheme 1, SOM 1: D, differentiated cells; DF, 
differentiation factors; DM, differentiation-promoting medium; ECM, extracellular 
matrix; GM, growth-promoting medium; GF, growth factors; NM, neutral medium;  
P, proliferating cells; PBS, phosphate buffered saline. 
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Manipulating cell fate in GM
Firstly, we have examined the behavior of cells in GM without 
any factors embedded in ECM. Consistent with previously 
published results (Morgan and  Partridge 2003; Conboy and   
Rando 2005), cells rapidly proliferate and do not differentiate 
in GM, ie, they incorporate BrdU and only less than 1% 
express the marker of differentiated myotubes, eMHC (Figure 
1a-GM, quantified in Figure 1b-GM). In contrast, embedded 
DF in ECM successfully promote myogenic differentiation of 
primary myoblasts (Figure 1a-GM + DF), as shown by their 
reduced proliferation and enhanced expression of eMHC. 
Interestingly, such directed differentiation occurs even in 
the presence of highly mitogenic GM, which contains 20% 
FBS and FGF-2 (Figure 1a-GM + DF, quantified in Figure 
1b-GM + DF). Figure 1b demonstrates quantification of 
multiple experiments and statistically shows that the effects 
caused by DF-modified ECM significantly promote the 
differentiation of myogenic cells exposed to mitogenic media. 
Specifically, cells attached to areas of DF-modified ECM 
show higher expression of eMHC
+ (number of cells at early 
stage of differentiation, D1, significantly rises from 0.5% to 
11.8%: p = 0.003). In addition, even though cells exposed 
to DF-modified ECM continue to proliferate, the rate was 
slower (Figure 1b: Number of proliferating cells P drops from 
20.9% in GM to 9.6% in GM + DF; p = 0.077) and a higher 
percentage of these cells expresses the differentiation marker, 
eMHC (Figure 1b-GM + DF: D1 = 11.8%). Thus, these 
findings reveal that it is possible to force the differentiation 
of cells under proliferative media conditions through DF-
modified ECM substrates.
Moreover, we achieved geometric control of cell fate 
determination, as clearly shown in Figure 1c, where an 
obvious interface between eMHC
+ and eMHC
- myogenic 
progenitor cells cultured under identical media conditions 
was created by exposing these cells to the different regions 
of ECM substrate (with vs without DF). 
Manipulating cell fate in DM
To confirm and extrapolate these findings, we tested 
whether the reciprocal cell fate determination could also 
be achieved within our experimental system. Specifically, 
we cultured cells in DM with unmodified vs GF-modified 
ECM. Unsurprisingly, fusion competent myoblasts terminally 
differentiate and form eMHC
+ myotubes when cultured in 
DM (Conboy and  Rando 2002; Morgan and  Partridge 2003; 
Conboy and  Rando 2005) (Figure 2a-DM, quantified in 
Figure 2b-DM). In contrast, Figure 2a-DM + GF shows that 
much fewer eMHC
+ myotubes are formed in the area where 
Figure 2  Geometric delay of myotube formation in DM by locally embedded 
growth factors. Myogenic progenitor cells have been plated at 50% confluency 
in chamber slides in DM. Cells were cultured for 48 hours and fixed. 
Immunofluorescence was performed with the indicated antibodies: α-BrdU (red), 
α-eMHC (green), and Hoechst (blue) was used to label all nuclei. 
(a) DM with unmodified ECM (DM) and DM with GF-modified ECM (DM+GF). 
There is a clear difference in the fate of cells cultured in DM on unmodified ECM 
(terminally differentiated, multinucleated myotubes) vs on GF-modified ECM 
(higher numbers of proliferative cells and smaller myotubes). (b) Quantification 
of P, early stage-differentiated cells with less than 2 nuclei (D1) and later stage-
differentiated cells with more than 2 nuclei (D2). Cells cultured on unmodified 
ECM in DM show low percentage of proliferating cells and high percentage of 
differentiated cells.  Alternately, when cultured on GF-modified ECM, cells show 
higher percentage of proliferating cells and lower numbers of differentiated cells.  
(c)  The boundary between unmodified ECM substrate and DF-modified ECM 
is shown (DM + GF interface). Magnified photographs (20x) of cells seeded on 
unmodified ECM (outside) and on GF-modified ECM (inside) areas of the culture 
plate are also shown. Cells were originally seeded at uniform confluency; however, 
as expected, cells adherent to the GF-modified ECM proliferated at a higher rate, 
resulting in a higher number of cells compared with those adherent to control 
ECM. Similar results have been obtained in at least 3 independent experiments. 
Magnification: (a) 20x; (c) “Outside”, “Inside” 20x; (c) “Interface” 10x.
cells are exposed to GF, compared with the area devoid of GF. 
Additionally, a significant fraction of cells incorporate BrdU 
(Figure 2a-DM + GF), thus overcoming the effect imposed by 
highly differentiating media when attached to GF-modified 
ECM substrates. 
Both the robustness and reproducibility of the afore-
mentioned regulation of cell fate by GF-signaling from 
specific areas of ECM were confirmed by the quantification 
of at least 3 replicated experiments, as illustrated in Figure 
2b-DM + DF. Proliferation (P) dramatically increases from 
0.6% in DM to 16.7% in DM + GF (p = 0.003) and the number 
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of cells at early stage of differentiation significantly drops 
from 18.9% to 2.9% (p = 0.004) 
Notably, similar to the data shown in Figure 1c, a clearly 
defined interface was created between the region of modified 
ECM, which contained embedded GF, and the unmodified 
control ECM area, thus allowing cells with different fates to 
coexist in the same culture medium (Figure 2c). This interface 
is discernable not only because some cells incorporate 
BrdU and some instead form myotubes, but also because of 
different cell densities. Specifically, there are approximately 
4 times more cells in the area of ECM embedded with GF. 
Since cells were uniformly seeded on the plate at uniform 
density, the higher number of cells can only be attributed to 
a predictably higher rate of cell proliferation in regions of 
GF-modified ECM.
It is well known that plating myoblasts at high density 
will lead to exit of cell cycle and differentiation, even in 
the presence of GM (Conboy and Rando 2002; Morgan 
and Partridge 2003). Thus, we decided to test whether we 
can inhibit differentiation under that specific condition. 
Even under high cell density (80% confluency), myogenic 
differentiation is delayed by GF-modified ECM, although 
not completely avoided (Supplemental Online Material, 
SOM 1). Remarkably, when plated at high density, cells 
attached to GF-modified ECM area show higher levels of 
both proliferation and differentiation (SOM 1). Therefore, 
as cell numbers increase, differentiation seems inescapable, 
despite initial placement of GF into ECM substrate. 
Manipulating cell fate in NM
After characterizing the effect of modified ECM substrates 
on cell fate in strongly differentiating or mitogenic media, 
we tested our GF- and DF-modified ECM substrates in NM 
conditions. As expected, in NM condition myoblasts slowly 
SOM 1  Delay of myogenic differentiation by locally embedded growth factors 
into ECM under high cell density (80% confluency). Myogenic progenitor cells 
have been plated at 80% confluency in chamber slides in DM for 36 hours. 
Immunofluorescence was performed after fixation with the indicated antibodies: 
α-Ki67 (red), α-eMHC (green), and Hoechst (blue) was used to label all nuclei. As 
specified in Table 1, GF were embedded into ECM in geometric fashion, as shown 
in Scheme 1. Consistent with the control DM shown in Figure 2a-DM, cells outside 
the geometric boundary (outside) form eMHC-positive robust myotubes and do 
not proliferate. Myogenic cell differentiation is diminished, as indicated by the lower 
number of nuclei per myotubes, and some Ki67
+ proliferating cells persist inside 
the geometric boundary (inside). Thus, GF embedded in the ECM are capable of 
diminishing differentiation even when cell numbers increase, but differentiation 
seems inescapable despite initial placement of GF into ECM. Magnification: 10x.
Figure 3  Geometric control of proliferation or terminal differentiation in NM. 
Myogenic progenitor cells have been plated at 50% confluence in chamber slides 
in NM for 48 hours. Immunofluorescence was performed with the indicated 
antibodies: α-BrdU (red), α-eMHC (green), and Hoechst (blue) was used to label 
all nuclei.
(a) Cells cultured in NM on unmodified ECM substrate (NM) show no distinct 
tendency towards proliferation or differentiation. When cultured on GF-modified 
ECM (NM + GF) cells proliferate (BrdU incorporation) without any tendency 
to form myotubes and differentiate, ie, eMHC
+. Conversely, when exposed to 
DF-modified ECM (NM + DF), cells terminally differentiate (eMHC
+) and form 
myotubes while proliferation is reduced. (b) Quantification of P, early stage-
differentiated cells with less than 2 nuclei (D1), and later stage-differentiated cells 
with more than 2 nuclei (D2). When cultured in NM on unmodified ECM, cells 
infrequently differentiate and have slow proliferation rate. However, when cells 
are plated on GF-modified ECM (NM + GF) there is a much larger percentage of 
proliferating cells;  and when they are plated on DF-modified ECM (NM + DF) there 
are higher percentages of not only eMHC
+ differentiated cells but also yield higher 
percentages of multinucleated myotubes (D2). (c) Boundary between GF-modified 
ECM and unmodified ECM. There are higher numbers of proliferating cells on GF-
modified ECM (inside) than on the unmodified ECM (outside). Similar results have 
been obtained in at least 3 independent experiments. Magnification: (a) 20x; (c) 10x.
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proliferate and infrequently produce eMHC
+ terminally 
differentiated cells, which usually have no more than 1 or 
2 nuclei (Figure 3a-NM and quantified in Figure 3b-NM: 
fraction of proliferation cells P = 9.8% and cells at early stage 
of differentiation D1 = 9.1%). This verifies that NM does not 
impose any strong determination of cell fate, thus potentially 
allowing a more discernable effect of our selected factors 
on the myogenic proliferation and differentiation. It has not 
yet been determined whether the physiological environment 
in regenerating muscle is either mitogenic (proliferating), 
or differentiating or both–neutral. Since proliferation and 
differentiation overlap during tissue repair, neutral media 
conditions might mimic the environment of regenerating 
muscle more accurately than GM or DM alone. As shown 
in Figure 3a-NM + GF and quantified in Figure 3b-NM + GF, 
cells cultured on modified ECM with embedded GF robustly 
proliferate (fraction of proliferating cells P = 32.2%) and 
do not significantly differentiate (fraction of cells at early 
stage of differentiation D1 = 2.3%). This is confirmed by 
the robust incorporation of BrdU and absence of eMHC 
staining. In parallel, myoblasts attached to modified ECM 
containing embedded DF efficiently differentiate and lack 
proliferation (Figure 3a, NM + DF, quantified in Figure 3b, 
NM + DF;  fraction of proliferating cells P = 5.2%;  fraction 
of cells at early stage of differentiation D1 = 13.7%;  fraction 
of cells at late stage of differentiation D2 = 12.4%). As 
above, quantification of at least 3 replicated experiments 
demonstrated high reproducibility of this geometric 
regulation of myogenic cell fate determination (Figure 3b).
Consistently with data shown above, Figure 3c demon-
strates a clearly defined interface between cells with different 
rates of myogenic proliferation cultured in identical media 
(NM), which was created by the exposure of cells to the 
geometrically embedded GF into ECM. 
In summary, data presented in this work demonstrate that 
GF and DF geometrically placed in adhesion substrates of 
myogenic progenitor cells compete against culture media for 
myogenic cell fate determination. As expected, embedding 
GF and DF into ECM substrate yields uniform and opposite 
effects on the proliferation and differentiation of myogenic 
progenitor cells. Importantly, the magnitude of the effects 
on either proliferation or differentiation is identical between 
uniformly modified ECM (Figures 1a, 2a, 3a) and the 
spatially modified areas of ECM (Figures 1c, 2c, 3c). This 
strongly suggests that geometrically embedded factors do not 
significantly diffuse throughout the ECM and that their initial 
concentrations are not diluted. Similar effects on proliferation 
and differentiation of myoblasts have been observed when 
these GF and DF (listed in Table 1) were added directly to 
culture media (data not shown). Thus, the biological activity 
of these factors remains the same whether they are embedded 
in ECM or added to culture media. However, unlike GF- or 
DF-modified ECM substrates, directly applied factors are, of 
course, not capable of creating a geometric boundary between 
cells with different fates coexisting in the same culture dish. 
There is no doubt that these factors added to media signal via 
their specific receptors on cells (Husmann et al 1996; Wagers 
and  Conboy 2005); thus, identical regulation of cell fate from 
ECM-embedded factors shown here strongly suggests that 
these factors also signal to cells attached to specific areas of 
modified ECM.
Discussion
This work demonstrates that myogenic cells at different 
stages of proliferation and differentiation can deliberately 
be orchestrated to coexist adjacent to each other on the 
same plate with identical culture media by their attachment 
to modified ECM substrates. Thus, cells with different fates 
and at different stages of the cell cycle can interact, and 
their direct interactions can be studied in the experimental 
system developed. During embryonic organogenesis, as well 
as in regenerating adult tissues, rapidly proliferating and 
terminally differentiated cells coexist and signal via both 
multiple cell–cell contacts and soluble molecules. Therefore, 
our developed technique can be used to identify the important 
molecular cross-talk regulating cell fate determination in 
embryonic development and in adult tissue repair. 
Yet another useful outcome of our work is the potential 
to develop a better microenvironment for cell transplantation 
studies. No existing method allows successful transplantation 
of myogenic progenitor cells. In this study, we have defined 
conditions that could improve the regenerative potential 
of transplanted cells, by allowing local control of their 
proliferation and terminal myogenic differentiation. In future 
applications, it would also be interesting to test whether 
negative effects of the aged or pathologic environments might 
be overcome, and therefore muscle regenerative potential 
could be controlled efficiently when myogenic progenitor 
cells are transplanted in the context of the modified ECM 
tested in this work. If necessary, the concentration and specific 
combinations of growth-promoting and differentiation-
promoting factors in the ECM could be attenuated to produce 
maximum myogenic potential in the presence of aged or 
pathologic environments. 
Our data strongly suggest that differentiation of myogenic 
progenitor cells always prevails over their growth, even International Journal of Nanomedicine 2006:1(2) 211
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when GF are embedded in ECM (Figures 2a, c and SOM 
1). Specifically, control cells cultured in DM on unmodified   
ECM fuse into multinucleated myotubes (Figure 2b-
DM;  fraction of cells at late stage of differentiation, 
D2 = 27.9%), while cells cultured on DF-modified ECM 
remain mono-nucleated in GM (Figure 1b-GM + DF; fraction 
of cells at early stage of differentiation, D1 = 11.8%, and no 
multinucleated cells have been found), which signifies a lower 
degree of terminal myogenic differentiation (Morgan and   
Partridge 2003). This suggests that DF-modified ECM have a 
differentiating effect, which is not completely dominant over 
the growth-promoting media (Figure 1b-GM + DF vs Figure 
2b-DM). Therefore, there is no danger of continuous cell 
proliferation or oncogenic phenotype from the exposure of 
myogenic progenitor cells to exogenous GF in the described 
method.
In contrast, we show that, once cells expand, new 
myotubes are likely to be formed more efficiently and 
robustly in the presence of GF-modified ECM (SOM 1). 
Such data are physiologically significant, since the loss of 
muscle strength and mass, known as muscle atrophy, often 
accompanies old age and muscle dystrophies. Thus, cell 
transplantation under conditions that are known to result in 
muscle hypertrophy could be especially beneficial for aged 
or pathologic organs. 
In summary, the approach presented in this work combines 
expertise in stem cell biology and bioengineering to create 
ECM adhesion substrates for deliberate geometric control 
of proliferation and differentiation of myogenic progenitor 
cells, which overrides the cell fate determination imposed 
by the culture media. Such modified ECM substrates could 
be used as a supportive microenvironment able to promote 
satellite cell expansion and differentiation in normal, aged, 
and disease-afflicted muscle. Additionally, this work may 
also serve as a model to engineer synthetic cellular niches 
to control and harness optimally the regenerative potential 
of stem cells in general.
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